Latest Diovan news
FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
posted September 14th
by modernClinician Editorial Team
by modernClinician Editorial Team
The U.S. Food and Drug Administration warns that it has found a second impurity in three lots of Torrent Pharmaceuticals' valsartan drug products.
No Apparent Short-Term Cancer Risk From Recalled Valsartan
posted September 13th
by modernClinician Editorial Team
by modernClinician Editorial Team
Users of valsartan contaminated with N-nitrosodimethylamine seem not to have increased cancer risk, according to a study published online Sept. 12 in The BMJ.
FDA Recalls Drugs Containing Active Ingredient Valsartan
posted July 19th
by modernClinician Editorial Team
by modernClinician Editorial Team
Several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure, are being recalled due to an impurity, N-nitrosodimethylamine, that has been found in the recalled products, according to the U.S. Food and Drug Administration.
Inclined Sleeper-Associated Sudden Unexpected Infant Deaths Continued After Recall 
FDA Now Providing Daily Updates on Adverse Events 
FDA Suspends U.S. License of Chikungunya Vaccine 
FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products .jpeg)
Breathing Interventions May Curb Cravings With Substance Use 
Adding Cognitive Behavioral Therapy, Self-Management Does Not Improve Opioid Taper Success 
About 30 Percent of Pediatric Surgery Patients Receive Opioid Rx .jpg)
Bradycardia Linked to Xylazine Detection in Opioid Overdose in ED Monthly Specialist Briefings
Stay Connected
